Cervical chromosome 9 polysomy: Validation and use as a surrogate endpoint biomarker in a 4-HPR chemoprevention trial

Gynecologic Oncology

Volumn 99, Issue 3 SUPPL., 2005, Pages

  Kim, Heung Gon ^a   Yamal, Jose Miguel ^a   Xu, Xiao Chun ^a   Hu, Wei ^a   Boiko, Iouri ^a   Linares, Adriana ^a   Vlastos, Anne Therese ^a   Atkinson, E Neely ^a   Malpica, Anais ^a   Hittelman, Walter N ^a   Follen, Michele ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cervix; Chemoprevention; Chromosome 9 polysomy; Randomized clinical trials; Surrogate end point biomarkers

Indexed keywords

FENRETINIDE;

CANCER INVASION; CANCER PREVENTION; CHROMOSOME 9; CHROMOSOME 9 POLYSOMY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENETIC MARKER; GENETIC STABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUMERICAL CHROMOSOME ABERRATION; PRIORITY JOURNAL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VALIDATION PROCESS;

ANEUPLOIDY; ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; FENRETINIDE; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; UTERINE CERVICAL NEOPLASMS;

EID: 28844466442     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.07.039     Document Type: Conference Paper

References (23)

1. B. Vogelstein, and K.W. Kinzler Cancer genes and the pathways they control Nat. Med. 8 10 2004 789 799
2. M.A. Novak, F. Michor, N.L. Komarova, and Y. Iwasa Evolutionary dynamics of tumor suppressor gene inactivation Proc. Natl. Acad. Sci. 101 29 2004 10635 10638
3. F. Michor, Y. Iwasa, B. Vogelstein, C. Lengauer, and M.A. Nowak Can chromosomal instability initiate tumorigenesis Semin. Cancer Biol. 15 1 2005 43 49
4. J. Kim, D.M. Shih, A. El-Naggar, J.S. Lee, C. Corrales, and S.M. Lippman Chromosome polysomy and histological characteristics in oral premalignant lesions Cancer Epidemiol., Biomakers Prev. 10 2001 319 325
5. V.A. Papadimitrakopoulou, D.D. Liu, L. Mao, D.M. Shin, A. El-Naggar, and H. Ibarguen Biolgoic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions Cancer Epidemiol., Biomarkers Prev. 11 2002 1605 1610
6. J.J. Lee, W.K. Hong, W.N. Hittelman, L. Mao, R. Lotan, and D.M. Shin Predicting cancer development in oral leukoplakia: ten years of translational research Clin Cancer Res. 6 2000 1702 1710
7. M. Follen, E.N. Atkinson, A. Malpica, W.N. Hittelman, R. Lotan, and L. West A randomized clinical trial of 4-hydroxyphenylretinamide for high grade squamous intraepithelial lesions of the cervix Clin. Cancer Res. 7 2001 3356 3365
8. J.-M. Yamal, D. Cox, W.N. Hittelman, I. Boiko, A. Malpica, and M. Guillaud Quantitative histopathology and chromosome 9 polysomy in a clinical trial of 4-HPR Gynecol. Oncol. 94 2004 296 306
9. R.C. Moon, H.J. Thompson, P.J. Becci, C.J. Grubbs, R.J. Gander, and D.L. Newton N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat Cancer Res. 39 1979 1339 1346
10. N. Oridate, S. Suzuki, M. Higuchi, M.F. Mitchell, W.K. Hong, and R. Lotan Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells J. Natl. Cancer Inst. 89 1997 1191 1198
11. E. Dmitrovsky N-(4-hydroxyphenyl) retinamide activation of a distinct pathway signaling apoptosis [editorial] J. Natl. Cancer Inst. 89 1997 1179 1181
12. N. Oridate, D. Lotan, M.F. Mitchell, W.K. Hong, and R. Lotan Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention J. Cell. Biochem. 23 1995 80 86 [Suppl]
13. R. Lotan, Z. Trizna, C.C. Zou, D. Lotan, M.F. Mitchell, and C.P. Zou Additive inhibitory effects of retinoids and interferon-α on the growth of human cervical carcinoma cells: lack of association with HPV status or retinoid receptor expression Int. J. Oncol. 8 1996 5 13
14. G.J. Kelloff, C.W. Boone, J.A. Crowell, V.E. Steele, R.A. Lubet, and L.A. Doody New agents for cancer chemoprevention J. Cell. Biochem. 26S 1996 1 28
15. U. Veronesi, G. De Palo, A. Costa, F. Formelli, and A. Decensi Chemoprevention of breast cancer with fenretinamide IARC Sci. Publ. 136 1996 87 94
16. U. Veronesi, G. De Palo, E. Marubini, A. Costa, F. Formelli, L. Mariani for the Fenretinide Trial Investigators Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer J. Natl. Cancer Inst. 91 1999 1847 1856
17. J.M. Kurie, J.S. Lee, F.R. Khuri, L. Mao, R.C. Morice, and J.J. Lee N-(4-Hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium Clin. Cancer Res. 6 2000 2973 2979
18. Y.I. Kim, A. Giuliano, K.D. Hatch, A. Schneider, M.A. Nour, and G.E. Dallal Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma Cancer 74 1994 893 899
19. J. Yokota, Y. Tsukada, T. Nakajima, M. Gotoh, Y. Shimosato, and N. Mori Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix Cancer Res. 49 1989 3598 3601
20. G.T.Y. Chung, D.P. Huang, K.W. Lo, M.K.M. Chan, and F.W.S. Wong Genetic lesion in the carcinogenesis of cervical cancer Anticancer Res. 12 1992 1485 1490
21. A.B. Mitra, V.V.V.S. Murty, R.G. Li, M. Pratap, U.K. Luthra, and R.S.K. Chaganti Allelotype analysis of cervical carcinoma Cancer Res. 54 1994 4481 4487
22. K. Heselmeyer, E. Schröck, S. du Manoir, H. Blegen, K. Shah, and R. Steinbeck Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix Proc. Natl. Acad. Sci. U. S. A. 93 1 1996 479 484
23. C. Lengauer, D.W. Kinzler, and B. Vogelstein Genetic instabilities in human cancers Nature 396 1998 (17 December) 643 649 10.1038/25292